Novo Nordisk restores enough Wegovy supply to meet prescriptions in US
Following issues at a contract manufacturer, Danish pharmaceutical firm Novo Nordisk had to announce that the supply for obesity drug Wegovy would be limited for some time. Now, the company has restored the supply to meet issued prescriptions in the US.
by marketwire, translated by daniel pedersen
Novo Nordisk announces on its US website that the the supply of weight loss treatment Wegovy has been restored for all five available dose strengths for patients in the US who have already been prescribed the drug.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Obesity business grows at Novo Nordisk despite Wegovy woes
For subscribers
.jpg)
.jpg)
.jpg&w=384&q=75)
